A randomized phase ii study comparing four different interferon therapies in patients with recalcitrant condyloma acuminata.

被引：0
|
作者：
Trizna, Z
Tyring, SK
机构：
[1] UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550
[2] UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77550
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1997年 / 108卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] A PHASE II MULTICENTRIC RANDOMIZED CONTROLLED STUDY OF CENTHAQUINE IN HEMORRHAGIC SHOCK PATIENTS
    Gulati, Anil
    Jain, Dinesh
    Agrawal, Nilesh
    Rahate, Prashant
    Das, Soumen
    Chowdhuri, Rajat
    Prabhu, Madhav
    Haveri, Sameer
    Dhibar, Deba
    Lavhale, Manish
    CRITICAL CARE MEDICINE, 2020, 48
  • [42] Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma
    McDermott, D. F.
    Sosman, J. A.
    Hodi, F. S.
    Gonzalez, R.
    Linette, G.
    Richards, J.
    Jakub, J. K.
    Beeram, M.
    Patel, K.
    Cranmer, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase II placebo-controlled, randomized, multicenter study to evaluate efficacy and safety of interferon beta-1a in patients with ulcerative colitis
    Musch, E
    Raedler, A
    Andus, T
    Kruis, W
    Schreiber, S
    Lorenz, A
    Krakamp, B
    Malchow, H
    Feurle, G
    Sezekly, G
    Krizova, V
    GASTROENTEROLOGY, 2002, 122 (04) : A431 - A431
  • [44] LASER PROSTATECTOMY FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA - A PROSPECTIVE RANDOMIZED STUDY COMPARING 2 DIFFERENT TECHNIQUES USING THE PROLASE-II FIBER
    BOON, TA
    VANSWOL, CFP
    VANVENROOIJ, GEPM
    BEERLAGE, HP
    VERDAASDONK, RM
    WORLD JOURNAL OF UROLOGY, 1995, 13 (02) : 123 - 125
  • [45] Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: A randomized phase II study
    Manns, Michael P.
    Gane, Edward
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy M.
    Caro, Luzelena
    Barnard, Richard J. O.
    Lee, Andrew W.
    HEPATOLOGY, 2012, 56 (03) : 884 - 893
  • [46] A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer
    Kosuge, T.
    Ueno, H.
    Matsuyama, Y.
    Yamamoto, J.
    Nakao, A.
    Egawa, S.
    Doi, R.
    Monden, M.
    Hatori, T.
    Tanaka, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 260 - 260
  • [47] A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
    Kay, Neil E.
    Strati, Paolo
    LaPlant, Betsy R.
    Leis, Jose F.
    Nikcevich, Daniel
    Call, Timothy G.
    Pettinger, Adam M.
    Lesnick, Connie E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    ONCOTARGET, 2016, 7 (48) : 78269 - 78280
  • [48] A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).
    Takahashi, Shunji
    Araki, Nobuhito
    Sugiura, Hideshi
    Ueda, Takafumi
    Takahashi, Mitsuru
    Morioka, Hideo
    Yonemoto, Tsukasa
    Hiraga, Hiroaki
    Hiruma, Toru
    Kunisada, Toshiyuki
    Matsumine, Akihiko
    Kawai, Akira
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] A randomized phase II study comparing capecitabine (C) with C plus oral cyclophosphamide (CCy) in patients (pts) with advanced breast cancer (BC)
    Harvey, V. J.
    Sharples, K.
    Isaacs, R.
    Jameson, M. B.
    Jeffery, M.
    McLaren, B.
    Pollard, S.
    Riley, G.
    Simpson, A.
    Findlay, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in patients with advanced NSCLC (POPLAR)
    Schulz, C.
    Spira, A., I
    Park, K.
    Mazieres, J.
    Vansteenkiste, J.
    Ballinger, M.
    Waterkamp, D.
    Fehrenbacher, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 104 - 104
12345